Blood–brain barrier (BBB) dysfunction is implicated as a key link between neuroinflammation and neurodegeneration in Alzheimer’s disease (AD). Peripheral inflammation may exacerbate cognitive decline by promoting BBB breakdown and impairing clearance of amyloid and tau, yet in vivo evidence for this hypothesis remains limited. We conducted a pilot cohort study to assess the feasibility of utilising dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to quantify BBB permeability in AD, and to explore associations with cognitive decline, peripheral inflammation, and neurodegeneration. Fourteen participants with clinically diagnosed AD and 16 matched controls underwent baseline clinical, blood, urine, and DCE-MRI assessments. Thirteen AD participants were clinically reassessed after 12 months. BBB permeability was quantified using Patlak modelling in whole brain, grey and white matter, and selected regions of interest. Serum cytokines, phosphorylated tau-181 (pTau-181), neurofilament light (NfL), and urinary neopterin were analysed. BBB permeability did not differ significantly between AD and controls across global or regional measures at baseline. However, higher baseline permeability in the left entorhinal cortex was significantly associated with greater cognitive decline over 12 months. AD participants exhibited elevated serum interferon-γ relative to controls, and higher baseline interleukin-6 was associated with faster cognitive decline. This pilot study supports feasibility of regional DCE-MRI measurement in people with AD. Larger biomarker-confirmed cohorts are warranted to evaluate prognostic utility and to clarify the interaction between peripheral inflammation, BBB dysfunction and clinical progression in AD.
The Qalb–CSF model showed the strongest inflammation-related signal, but these findings are exploratory and require validation in independent, longitudinal cohorts before an inflammation axis can be incorporated into an ATN(V)-based framework.
Azadeh Golduzian, Erik B. Erhardt, A. Caprihan et al.· Frontiers in Aging· 0 citations
Cerebral hypoperfusion, altered DTI-ALPS measures, and axonal injury were closely associated across the AD continuum, suggesting interrelated neurovascular, neurofluid-related tissue, and neurodegenerative alterations associated with cognitive impairment.
Yian Gao, Man-Xi Xu, Pei-Ling Ou et al.· NeuroImage· 0 citations
Neurovascular dysfunction may contribute to Parkinson’s disease (PD), but the extent and clinical relevance of blood-brain barrier alterations remain uncertain. We investigated regional blood-brain barrier permeability, fractional plasma volume, and choroid plexus contrast kinetics in patients with PD using dynam...
Sapir Fajerzstein, Gadi Maayan Eshed, Sheida Mirloo et al.· Fluids and Barriers of the C...· 0 citations
Retinal neuronal and microvascular alterations are associated with AD-related molecular pathology, cerebral neurodegeneration, APOE ε4-related vulnerability, and cognitive impairment.
Xiao-Qian Luan, Jia-Ning Shen, You-Jie Wang et al.· Translational Vision Science...· 0 citations
Abstract Age-related cognitive decline is a common and growing public health challenge, associated with loss of independence, reduced quality of life, increased caregiver burden and substantial healthcare and societal costs. Yet cognitive decline in ageing is heterogeneous, and current clinical constructs do not reliab...
Blood-brain barrier (BBB) dysfunction is increasingly recognized as an early pathological event in sporadic Alzheimer’s disease (AD), which represents over 95% of cases. Vascular risk factors and cerebral insulin resistance are considered potential contributors to its initiation. This review synthesizes evidence availa...
Karen León-Arcia, Humberto Martínez-Orozco, Magdalena Guerra-Crespo et al.· Journal of Molecular Neurosc...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.